Previous trials, including the ENHANCE trial, have raised doubts about the clinical benefits of adding ezetimibe to high-dose statin therapy. The ARBITER 6-HALTS trial added further weight to the results of ENHANCE, wherein the ARBITER trial demonstrated that extended-release niacin was superior to ezetimibe as adjunctive therapy to high-dose statins in slowing atherosclerosis. However, this study was not based on clinical outcomes, but rather on measuring carotid intima-media thickness (CIMT). In addition, the ARBITER trial was relatively small, based on 208 patients completing the trial. Are these data enough to impact clinical use of ezetimibe and niacin, or should we await results of further large-scale trials? Dr. Christopher Cannon, associate professor of medicine at Harvard Medical School and editor-in-chief of the American College of Cardiology's Cardiosource, weighs in on these questions and more regarding adjunctive therapy to high-dose statins, with host Dr. Jack Lewin.
The ARBITER 6-HALTS Trial: Clinical Implications
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Previous trials, including the ENHANCE trial, have raised doubts about the clinical benefits of adding ezetimibe to high-dose statin therapy. The ARBITER 6-HALTS trial added further weight to the results of ENHANCE, wherein the ARBITER trial demonstrated that extended-release niacin was superior to ezetimibe as adjunctive therapy to high-dose statins in slowing atherosclerosis. However, this study was not based on clinical outcomes, but rather on measuring carotid intima-media thickness (CIMT). In addition, the ARBITER trial was relatively small, based on 208 patients completing the trial. Are these data enough to impact clinical use of ezetimibe and niacin, or should we await results of further large-scale trials? Dr. Christopher Cannon, associate professor of medicine at Harvard Medical School and editor-in-chief of the American College of Cardiology's Cardiosource, weighs in on these questions and more regarding adjunctive therapy to high-dose statins, with host Dr. Jack Lewin.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Updates From the 7th World Symposium Task Force
Pulmonary Hypertension Management: Practice Trends and Updates
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Respiratory Dysfunction in Neuromuscular Disorders: Evaluating Symptoms
Clinical Strategies for Assessing Sleep Disturbances in Postpartum Patients
Reducing the Risk of Postpartum Depression Through Sleep Interventions
Improving the IUD Experience: Evidence-Based Pain Management Approaches
Bladders, Breakthroughs, and Bold New Therapies: Key Updates at AUA 2025
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?